Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin and Lower Dose Chemotherapy Plus Blinatumomab Compared to Usual Chemotherapy Plus Blinatumomab for Older Adults With B-Cell ALL or B-Cell LBL
NCT05303792Phase 2Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Event-Free Survival up to 5 years. Started Jun 2023; status: active, not recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT05303792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303792.